Background— Vitamin K antagonist (VKA) therapy is increasingly being used for the prevention
of venous thromboembolism and stroke in atrial fibrillation. Bleeds are the major concern …

The optimal duration of anticoagulation in patients with venous thromboembolism (VTE) is
uncertain. We investigated whether persistently negative D-dimers in patients with vein …

p-Coumaric acid (3-(4-hydroxyphenyl)-2-propenoic acid; 4CA), is a ubiquitous plant
metabolite with antioxidant and anti-inflammatory properties. The antiplatelet activity of this …

Objectives : We sought to evaluate the rate of bleeding in relation to age (<80 and ≥80 years),
the quality of anticoagulation (expressed as time spent in international normalized ratio …

This study sought to compare Multiplate impedance platelet aggregometry (IPA) with light
transmission aggregometry (LTA) and the PFA-100 for determining the prevalence of residual …

After a first episode of pulmonary embolism (PE), two major problems need to be considered:
risk of recurrence when anticoagulation is stopped, and risk of chronic thromboembolic …

Essentials • Currently, DOACs are given at fixed doses and do not require laboratory monitoring.
• Direct oral anticoagulant‐specific measurements were performed at trough and peak. …

Residual venous obstruction (RVO) could improve the stratification of the risk of recurrence
after unprovoked deep vein thrombosis (DVT), but results from clinical studies and study-…

The efficacy of adjusted-dose oral anticoagulant treatment (OAT) in the prevention of stroke
in atrial fibrillation (AF) is well documented. Available data show that AF patients are widely …

Stroke Risk Stratification. Introduction: Appropriate stroke risk stratification is essential to
ensure suitable tailoring of antithrombotic therapy. The objective of this study was to assess the …